Prime Medicine, Inc. (NASDAQ:PRME) Stock Has Average Price Target of $7.86

Shares of Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $7.86.

A number of research firms have recently weighed in on PRME. Wall Street Zen upgraded shares of Prime Medicine from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Citigroup restated a “market outperform” rating on shares of Prime Medicine in a research report on Friday, September 25th. Jefferies Financial Group reaffirmed a “market outperform” rating on shares of Prime Medicine in a report on Monday, September 28th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Prime Medicine in a research report on Friday, September 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research note on Monday, August 31st.

Check Out Our Latest Analysis on PRME

Prime Medicine Stock Performance

Prime Medicine stock opened at $4.27 on Wednesday. The firm has a 50 day moving average of $3.70 and a 200 day moving average of $3.51. The firm has a market capitalization of $774.49 million, a price-to-earnings ratio of -4.45 and a beta of 2.13. Prime Medicine has a 12-month low of $2.67 and a 12-month high of $5.91.

Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Prime Medicine had a negative return on equity of 222.88% and a negative net margin of 2,497.56%. The business had revenue of $4.21 million for the quarter. On average, analysts predict that Prime Medicine will post -0.97 EPS for the current year.

Prime Medicine News Summary

Investors following PRME have been watching these news items:

  • Positive Sentiment: Third-quarter revenue was about $4.2 million, above the cited FactSet estimate of $1.3 million. The loss of $0.22 per share was also narrower than the $0.23 consensus estimate and improved from a $0.32 loss a year earlier. Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
  • Positive Sentiment: Prime Medicine closed a public offering that brought in approximately $143.7 million in gross proceeds. The added capital could help fund development of its Prime Editing programs across liver, lung, immunology and oncology. Prime Medicine Announces Closing of Public Offering
  • Negative Sentiment: The offering involved 41.1 million new shares sold at $3.50 each, diluting existing shareholders and potentially creating near-term selling pressure. Offering details

Institutional Trading of Prime Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Prime Medicine in the third quarter worth approximately $28,000. Royal Bank of Canada increased its holdings in Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock worth $32,000 after purchasing an additional 4,365 shares during the period. Wealthfront Advisers LLC bought a new stake in Prime Medicine during the 1st quarter valued at $36,000. Kingsview Wealth Management LLC bought a new stake in Prime Medicine during the 2nd quarter valued at $37,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Prime Medicine in the 1st quarter worth $41,000. 70.37% of the stock is owned by hedge funds and other institutional investors.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Featured Stories

Analyst Recommendations for Prime Medicine (NASDAQ:PRME)

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.